The MYB signaling pathway has been shown to up-regulate multiple target genes, including vascular endothelial growth factor a, fibroblast growth factor 2, and c-KIT.[16] Anlotinib can be targeted to inhibit these targets.[4] We suspect that this is a mechanism by which anlotinib is effective in ACC treatment. This evidence concerns the gene KIT and adrenal cortex carcinoma.